Trials / Completed
CompletedNCT00646386
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab | 40 mg eow Week 0 - Week 24 |
| DRUG | placebo for adalimumab | 40 mg eow Week 0 - Week 24 |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2004-04-01
- First posted
- 2008-03-28
- Last updated
- 2008-03-28
Source: ClinicalTrials.gov record NCT00646386. Inclusion in this directory is not an endorsement.